Researchers at WashU Medicine have found that glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide and tirzepatide, were associated with significantly lower risks of heart attack, heart failure and death among adults with serious mental illness, type 2 diabetes and obesity.
GLP-1 drugs linked to lower cardiovascular risk in people with serious mental illness (Links to an external site)














































